Precision BioSciences Inc (DTIL)

[jondoeuk]

The company's long-term goal is for PBCAR19B to displace auto products. The program was strategically paused in Q1 to implement an optimised manufacturing process, which was to increase a T-cell memory subset with stem cell-like properties. Data on some patients treated at DL2 (540M cells) with the new lots, as well as those from DL1 (270M cells) could either be presented at ASH or an investor event. However, it won't be until next year until there will be a longer follow-up for durability. So until then we won't have an idea if it really could do what they hope.

Moving to PBCAR269A with nirogacestat, I have mixed views about this program. I know the CAR can't target cells with low BCMA levels (which is why they added niro). Also, the space is becoming more crowed, and many are moving toward dual targeted CARs. If they would do the same, but target other antigens that aren't being pursued by many, that could be a better long-term strategy.